The therapeutic potential of donepezil may also be of great value in children with epilepsy caused by GoF variants in KCNQ2, since its administration was recently shown to confer robust protection against induced seizures in a mouse model of Dravet syndrome (Wong et al., 2019). Here, KCNQ2 is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.